Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > New podcast today

<< Previous

Bullboard Posts

Next >>

Comment by canadafanon Oct 29, 2024 12:33pm

135 Views

Post# 36287012

RE:RE:New podcast today

thanks for the recent links. I took the time to read the first publiction. and also listen to the interview.
Irecomend , the interview.
As the interview does a god job of expaining various medical details. Regarding The Mbc.
It was low key. meaning not hype. just the facts as they say.
Off hand , it has now been 3 weeks since they released the 'accelertated approval" option N.R.

<< Previous

Bullboard Posts

Next >>

These cold weather stocks are looking to heat up for winter